Every 8-K that Research Alliance Corporation III (RACC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RACC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RACC filings page.
Research Alliance Corporation III agreed to merge with OHB Pediatrics Ltd. (Oak Hill Bio) in an all‑stock business combination under which RACC will acquire 100% of Oak Hill Bio after redomesticating from the Cayman Islands to Delaware. Oak Hill Bio will become a wholly owned subsidiary and the combined company is expected to list on the Nasdaq Capital Market as Oak Hill Bio, Inc.
Oak Hill Bio shareholders will receive newly issued RACC common stock, with Closing Consideration equal to the Adjusted Equity Value divided by $10.00 per share. Adjusted Equity Value is defined as a $160,000,000 Base Equity Value plus the Company SAFE Amount, which comes from $45,000,000 of SAFEs bearing 8% annual interest that convert into equity immediately before closing.
Funding for the combined business includes a RA Capital backstop to purchase up to 7,500,000 shares at $10.00 per share to offset any RACC shareholder redemptions, a $55,000,000 PIPE of common stock and pre‑funded warrants at $10.00, and previously funded SAFEs. Oak Hill Bio and RACC state that these sources together are expected to provide roughly $175,000,000 in gross proceeds before expenses. Closing is targeted for the second half of 2026, subject to HSR clearance, effectiveness of an S‑4 registration/proxy statement, Nasdaq listing approval and shareholder approvals. Oak Hill Bio’s lead asset is rugonersen, an antisense oligonucleotide in a pivotal Phase 3 BEACON trial for Angelman syndrome, a rare neurodevelopmental disorder affecting about 30,000 diagnosed patients across the U.S. and EU5.
Research Alliance Corporation III completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75,000,000 in gross proceeds. A concurrent private placement of 275,000 Class A shares added $2,750,000. In total, $75,000,000 was placed into a segregated trust account for the benefit of public shareholders, while $1,255,049 of cash remained available for working capital. The audited balance sheet shows Class A shares subject to possible redemption of 7,500,000 shares at $10.00 each and a shareholders’ deficit of about $1.1 million, typical for a newly formed blank check company before a business combination.
Research Alliance Corporation III, a healthcare-focused special purpose acquisition company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000.
The company also completed a private placement of 275,000 Class A shares to its sponsor at $10.00 per share for $2,750,000. As of May 21, 2026, $75,000,000 of IPO and private placement net proceeds, including a $2,250,000 deferred underwriting commission, were placed in a trust account for the benefit of public shareholders.
In connection with the IPO, Michael F. MacLean and Timothy J. Miller joined the board and its key committees, each holding 39,130 Class B founder shares after a share transfer and capitalization. The company adopted amended constitutional documents and listed its Class A shares on the Nasdaq Capital Market under the symbol RACC.